" class="no-js "lang="en-US"> Synaptogenix - Medtech Alert
Friday, September 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Synaptogenix | Pharmtech Focus

Synaptogenix

About Synaptogenix

Synaptogenix
OUR MISSION

Discovering restorative, novel therapeutics for patients with life altering neurodegenerative diseases and developmental disorders.

  • Clinically meaningful restoration of cognitive function
  • Regeneration of cerebral connections
  • Two Phase II pilot study trials completed
  • Biomarkers track cognitive improvement
  • Extensive toxicity safety profile
  • Partnerships with National Cancer Institute, National Institute of Health, and National Institute of Aging

Related Story

Clinical Trials

 Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease | PTF

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

December 16 2022

Synaptogenix, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, has announced topline data […]

Fundraising

 Synaptogenix Announces $12.5 Million Private Placement | Pharmtech Focus

Synaptogenix Announces $12.5 Million Private Placement

June 16 2021

Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced […]